Navigation Links
Transgenomic and Power3 Medical Report Identification of Abnormal Serum Proteins in Parkinson's Disease
Date:9/2/2009

OMAHA, Neb. and HOUSTON, Sept. 2 /PRNewswire-FirstCall/ -- Transgenomic, Inc. (OTC Bulletin Board: TBIO) and Power3 Medical Products, Inc. (OTC Bulletin Board: PWRM) today announced the advance on-line publication of a clinical research paper entitled "Abnormal Serum Concentrations of Proteins in Parkinson's Disease" in the scientific journal Biochemical and Biophysical Research Communications. The study demonstrates the usefulness of a protein biomarker panel to distinguish Parkinson's disease (PD) patients from age-matched normal controls independent of the severity of symptoms, using clinical blood serum samples.

The analytic technology forms the basis for the NuroPro(R)PD test for PD being commercialized by Transgenomic as per a licensing/collaboration agreement with Power3 Medical signed in early 2009. The publication of the peer-reviewed article is a significant validation milestone in the ongoing clinical development of the NuroProPD diagnostic assay.

The article describes the use of analytically validated quantitative 2D gel electrophoresis to identify protein biomarkers for diagnosing PD using serum from routinely collected blood samples. 57 protein biomarkers, which had been discovered using retrospective blood serum samples from various neurodegenerative diseases, were then applied specifically to PD in a prospective clinical investigation using freshly collected blood serum from PD patients and age-matched normal controls. A multi-variate statistical method, stepwise linear discriminant analysis, selected a combination of 21 of the biomarkers as optimal to distinguish PD patients from controls. When applied to the PD samples, the 21-protein set had sensitivity of 93.3% (52 of 56 PD correctly classified) and specificity of 92.9% (28 of 30 controls correctly classified); 15 of 15 patients with mild and 28 of 30 with moderate to severe symptoms were correctly classif
'/>"/>

SOURCE Transgenomic, Inc.; Power3 Medical Products, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Transgenomic, Inc. Reports Second Quarter 2009 Results
2. Reminder: Transgenomic Inc. Announces Second Quarter 2009 Earnings Release Conference Call Webcast
3. Webcast Alert: Transgenomic Inc. Announces Second Quarter 2009 Earnings Release Conference Call Webcast
4. Transgenomic, Inc. Announces Appointment of New Board Members
5. Transgenomic, Inc. Reports First Quarter 2009 Results
6. Reminder: Transgenomic Inc. Announces First Quarter 2009 Earnings Release Conference Call Webcast
7. Transgenomic and Power3 Medical Introduce NuroPro(R) Tests for Alzheimers and Parkinsons Diseases at AAN Annual Meeting
8. Webcast Alert: Transgenomic Inc. Announces First Quarter 2009 Earnings Release Conference Call Webcast
9. Transgenomic Completes Licensing Option With Dana-Farber Cancer Institute on Cold-PCR for Enrichment of DNA Mutations
10. Polycystic Kidney Disease Assay at Cornell University Uses Transgenomics Surveyor Nuclease & WAVE Technology
11. Transgenomic, Inc. Reports Fourth Quarter and Fiscal Year 2008 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/2/2015)... ... ... have been used in countless labs for decades. In the past, people had to ... expected, this was a daunting and tiring process looking at endless data tables and charts. ... navigate the complex catalog structure. , Now thanks to FireflySci, scientists are throwing away those ...
(Date:7/2/2015)... ... 02, 2015 , ... Sleepless nights will become obsolete as Luzi , ... Indiegogo campaign on June 23. Sound sleepers and the sleep deprived both will love ... use, while the integration of the Bluetooth speaker, alarm clock and ability to charge ...
(Date:7/1/2015)... Mass. , July 1, 2015   ... most frequently cited advantages of Otezla are its ... safety profile, as reported by surveyed rheumatologists. Otezla ... launched for the treatment of active psoriatic arthritis ... The current standard of care includes conventional oral ...
(Date:7/1/2015)... July 1, 2015  Axovant Sciences Ltd. (NYSE: ... the treatment of dementia, today announced that the ... 22 at 5:45 p.m. EDT following its presentation ... International Conference 2015 (AAIC). The ... , Dr. Lawrence Friedhoff , Chief Development ...
Breaking Biology Technology:New Cuvette E-Commerce Website Launched by FireflySci 2Luzi Smart Lamp Recently Launched Indiegogo Campaign 2Luzi Smart Lamp Recently Launched Indiegogo Campaign 3Surveyed Rheumatologists Report That Otezla's Oral Administration is its Single Greatest Advantage Over Currently Available Treatment Options 2Surveyed Rheumatologists Report That Otezla's Oral Administration is its Single Greatest Advantage Over Currently Available Treatment Options 3Axovant Sciences To Host Investor Briefing And Live Webcast During AAIC 2015 Meeting 2Axovant Sciences To Host Investor Briefing And Live Webcast During AAIC 2015 Meeting 3
... company secrets. He thinks business meetings can be toxic as ... to improve the flow of communication, and he thinks employees ... , ,There is a method to Jason Fried's ... the recent Wisconsin Entrepreneurs' Conference in Milwaukee. , ,The founder ...
... revenues surge by 86 percent and its net loss grow ... issued since it officially became a publicly traded company. ... research collaboration with Lawrence Livermore National Laboratory that ... , , First quarter financials , ,TomoTherapy, which raised ...
... up the Vista/Office 2007 learning curve for the ... is in the basement. Frustration has reached all-time highs, and ... my e-mail, launch a presentation, and review a financial spreadsheet. ... challenge started when I got a new laptop. My three-year ...
Cached Biology Technology:Visions: Chicago software exec Jason Fried breaks (almost) all the rules 2Visions: Chicago software exec Jason Fried breaks (almost) all the rules 3TomoTherapy reports 86% revenue jump, $131M net loss in Q1 2TomoTherapy reports 86% revenue jump, $131M net loss in Q1 3Picking Vista sure seemed like a good idea at the time 2Picking Vista sure seemed like a good idea at the time 3
(Date:6/16/2015)... 16, 2015 Fingerprint Cards has received ... in the company,s portfolio from one of its module partners ... mainly take place during the third quarter 2015. The sensors ... . Jörgen Lantto, CEO of FPC, comments: ...   growing interest from smartphone OEMs in integrating touch fingerprint ...
(Date:6/15/2015)... , Jun. 15, 2015 NXT-ID, Inc. (NASDAQ: ... focused on the growing mobile commerce market, announces that its ... showcased to media at Digital Experience! @ NYC June 18th. ... showcase of the latest innovation in technology to over 300 ... be held at the Metropolitan Pavilion in New ...
(Date:6/9/2015)...   MedNet Solutions , an innovative SaaS-based eClinical ... research, will be providing demonstrations of its ... Drug Information Association (DIA) Annual Meeting in ... will include previews of many exciting new enhancements that ... iMedNet 2015 Feature 1 Release. ...
Breaking Biology News(10 mins):FPC Receives Order for Touch Fingerprint Sensors of 375 MSEK 2Wocket Smart Wallet Exhibiting at Pepcom Digital Experience! @ NYC June 18th 2Wocket Smart Wallet Exhibiting at Pepcom Digital Experience! @ NYC June 18th 3MedNet To Provide Sneak Peeks Of Its iMedNet "2015 Feature 1 Release" At The DIA Annual Meeting 2MedNet To Provide Sneak Peeks Of Its iMedNet "2015 Feature 1 Release" At The DIA Annual Meeting 3
... SynCardia Systems, Inc. ( www.syncardia.com ), manufacturer of ... today that University Hospital of Nantes successfully transplanted 51-year-old ... of support. Mrs. Mouche is a French gypsy who ... km from Nantes. "We first implanted Mrs. ...
... sixty atmospheric pollutants have been studied using the data ... to 2009. Concentrations of pollutants in Lapland are very ... in Southern Finland. Many of the concentrations studied remained ... a decreasing trend. Lower concentrations were measured ...
... at the University of Leeds have come a step closer ... Their findings, published in the International Journal of ... developed to tackle other cancers should be considered as a ... as tamoxifen, that target a protein responsible for tumour growth, ...
Cached Biology News:SynCardia's Total Artificial Heart Rescues LVAD Patient with Right Ventricular Failure 2SynCardia's Total Artificial Heart Rescues LVAD Patient with Right Ventricular Failure 3Air quality has continued to improve in Finnish Lapland 2Another step toward resisting breast cancer 2